Better-than-expected quarterly earnings for Pfizer

May 04, 2021
Better-than-expected quarterly earnings for Pfizer

One of the largest American drug makers, Pfizer, beat estimates in first quarter of 2021

Compared with the 77 cents earnings-per-share expected by Wall Street, Pfizer reported an adjusted EPS of 93 cents. The revenue figures came in at $14.58 billion, topping the $13.51 billion consensus. In Q1, Pfizer reported sales of $3.5 billion for its COVID-19 vaccine developed alongside BioNTech.

Moreover, Pfizer revealed that by the end of May wants to apply for full US approval of its vaccine. If approval it is granted, Pfizer will be able to sell its vaccine directly to consumers. Additionally, the Food and Drug Administration is set to authorize the vaccine for use in adolescents aged 12-15. In September in November, Pfizer will file for authorization for its vaccine for use in toddlers, younger children, and infants, respectively.

The company raised its full-year sales forecast to $26 billion, from an initial $15 billion. Moreover, by the end of July, Pfizer’s goal is to deliver 300 million doses.

Following the news, Pfizer stock price gained 1.4%.


This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.
This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of

Recently Added

Most Affected Instruments

pfizer chart